Inhibition of angiotensin-converting enzyme and phosphodiesterase type 5 improves endothelial function in heart failure

Clinical Science

Volumn 108, Issue 4, 2005, Pages 331-338

  Hryniewicz, Katarzyna ^a   Dimayuga, Clarito ^b   Hudaihed, Alhakam ^a   Androne, Ana Silvia ^a   Zheng, Haoyi ^a   Jankowski, Krzysztof ^c   Katz, Stuart D ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Columbia Univ Coll of Phys/Surgs ^*  (United States)

^c UNIVERSITY OF WARSAW   (Poland)

Author keywords

Angiotensin converting enzyme (ACE); Endothelium; Heart failure; Neurohormone; Nitric oxide; Phosphodiesterase (PDE)

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; RAMIPRIL; SILDENAFIL;

ADULT; AGED; ARTERY DILATATION; ARTICLE; BRACHIAL ARTERY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG POTENTIATION; ECHOGRAPHY; ENDOTHELIUM; ENZYME INHIBITION; FEMALE; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; BRACHIAL ARTERY; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; FEMALE; HEART FAILURE, CONGESTIVE; HEART RATE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; NOREPINEPHRINE; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PIPERAZINES; PROSPECTIVE STUDIES; RAMIPRIL;

EID: 17144428934     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20040266     Document Type: Article

References (46)

1. Kubo, S. H., Rector, T. S., Bank, A. J., Williams, R. E. and Heifetz, S. M. (1991) Endothelium-dependent vasodilation is attenuated in patients with heart failure. Circulation 84, 1589-1596
2. Katz, S. D., Biasucci, L., Sabba, C. et al. (1992) Impaired endothelium-mediated vasodilation in the peripheral vasculature of patients with congestive heart failure. J. Am. Coll. Cardiol. 19, 918-925
3. Treasure, C. B., Vita, J. A., Cox, D. A. et al. (1990) Endothelium-dependent dilation of the coronary microvasculature is impaired in dilated cardiomyopathy. Circulation 81, 772-779
4. Hamilton, C. A., Miller, W. H., Al-Benna, S. et al. (2004) Strategies to reduce oxidative stress in cardiovascular disease. Clin. Sci. 106, 219-234
5. Maguire, S. M., Nugent, A. G., McGurk, C., Johnston, G. D. and Nicholls, D. P. (1998) Abnormal vascular responses in human chronic cardiac failure are both endothelium dependent and endothelium independent. Heart 80, 141-145
6. Nakamura, M., Yoshida, H., Arakawa, N., Mizunuma, Y., Makita, S. and Hiramori, K. (1996) Endothelium-dependent vasodilatation is not selectively impaired in patients with chronic heart failure secondary to valvular heart disease and congenital heart disease. Eur. Heart J. 17, 1875-1881
7. Katz, S. D., Balidemaj, K., Homma, S., Wu, H., Wang, J. and Maybaum, S. (2000) Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J. Am. Coll. Cardiol. 36, 845-851
8. Joannides, R., Bizet-Nafeh, C., Costentin, A. et al. (2001) Chronic ACE inhibition enhances the endothelial control of arterial mechanics and flow-dependent vasodilatation in heart failure. Hypertension 38, 1446-1450
9. Hornig, B., Arakawa, N., Haussmann, D. and Drexler, H. (1998) Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure. Circulation 98, 2842-2848
10. Reffelmann, T. and Kloner, R. A. (2003) Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. Circulation 108, 239-244
11. Yan, C., Kim, D., Aizawa, T. and Berk, B. C. (2003) Functional interplay between angiotensin II and nitric oxide: cyclic GMP as a key mediator. Arterioscler., Thromb., Vasc. Biol. 23, 26-36
12. Wolin, M. S. (2000) Interactions of oxidants with vascular signaling systems. Arterioscler., Thromb., Vasc. Biol. 20, 1430-1442
13. Vanhoutte, P. M., Boulanger, C. M. and Mombouli, J. V. (1995) Endothelium-derived relaxing factors and converting enzyme inhibition. Am. J. Cardiol. 76, 3E-12E
14. Morrison, L. K., Harrison, A., Krishnaswamy, P., Kazanegra, R., Clopton, P. and Maisel, A. (2002) Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J. Am. Coll. Cardiol. 39, 202-209
15. Ball, S. G. and Robertson, J. I. (1987) Clinical pharmacology of ramipril. Am. J. Cardiol. 59, 23D-27D
16. Straeter-Knowlen, I. M., Dell'italia, L. J., Dai, J. et al. (1999) ACE inhibitors in HF restore canine pulmonary endothelial function and ANG II vasoconstriction. Am. J. Physiol. 277, H1924-H1930
17. Finta, K. M., Fischer, M. J., Lee, L., Gordon, D., Pitt, B. and Webb, R. C. (1993) Ramipril prevents impaired endothelium-dependent relaxation in arteries from rabbits fed an atherogenic diet. Atherosclerosis 100, 149-156
18. Berkenboom, G., Langer, I., Carpentier, Y., Grosfils, K. and Fontaine, J. (1997) Ramipril prevents endothelial dysfunction induced by oxidized low-density lipoproteins: a bradykinin-dependent mechanism. Hypertension 30, 371-376
19. de Graeff, P. A., Kingma, J. H., Dunselman, P. H., Wesseling, H. and Lie, K. I. (1987) Acute hemodynamic and hormonal effects of ramipril in chronic congestive heart failure and comparison with captopril. Am. J. Cardiol. 59, 164D-170D
20. Goldstein, I., Lue, T. F., Padma-Nathan, H., Rosen, R. C., Steers, W. D. and Wicker, P. A. (1998) Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N. Engl. J. Med. 338, 1397-1404
21. Erratum (1998) N. Engl. J. Med. 339, 59
22. Corbin, J. D. and Francis, S. H. (1999) Cyclic GMP phosphodiesterase-5: target of sildenafil. J. Biol. Chem. 274, 13729-13732
23. Jeremy, J. Y., Ballard, S. A., Naylor, A. M., Miller, M. A. and Angelini, G. D. (1997) Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro. Br. J. Urol. 79, 958-963
24. Ballard, S. A., Gingell, C. J., Tang, K., Turner, L. A., Price, M. E. and Naylor, A. M. (1998) Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J. Urol. 159, 2164-2171
25. Halcox, J. P., Nour, K. R., Zalos, G. et al. (2002) The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J. Am. Coll. Cardiol. 40, 1232-1240
26. Desouza, C., Parulkar, A., Lumpkin, D., Akers, D. and Fonseca, V. A. (2002) Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. Diabetes Care 25, 1336-1339
27. Corbin, J. D. and Francis, S. H. (2002) Pharmacology of phosphodiesterase-5 inhibitors. Int. J. Clin. Pract. 56, 453-459
28. Bocchi, E. A., Guimaraes, G., Mocelin, A., Bacal, F., Bellotti, G. and Ramires, J. F. (2002) Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure: a double-blind, placebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction. Circulation 106, 1097-1103
29. Webb, D. J., Freestone, S., Allen, M. J. and Muirhead, G. J. (1999) Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist. Am. J. Cardiol. 83, 21C-28C
30. Vardi, Y., Klein, L., Nassar, S., Sprecher, E. and Gruenwald, I. (2002) Effects of sildenafil citrate (viagra) on blood pressure in normotensive and hypertensive men. Urology 59, 747-752
31. Rajagopalan, S., Kurz, S., Munzel, T. et al. (1996) Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/ NADPH oxidase activation. Contribution to alterations of vasomotor tone. J. Clin. Invest. 97, 1916-1923
32. Mollnau, H., Wendt, M., Szocs, K. et al. (2002) Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/ cGMP signaling. Circ. Res. 90, E58-E65
33. Rybalkin, S. D., Rybalkina, I. G., Feil, R., Hofmann, F. and Beavo, J. A. (2002) Regulation of cGMP-specific phosphodiesterase (PDE5) phosphorylation in smooth muscle cells. J. Biol. Chem. 277, 3310-3317
34. Kim, D., Rybalkin, S. D., Pi, X. et al. (2001) Upregulation of phosphodiesterase 1A1 expression is associated with the development of nitrate tolerance. Circulation 104, 2338-2343
35. Haneda, M., Kikkawa, R., Maeda, S. et al. (1991) Dual mechanism of angiotensin II inhibits ANP-induced mesangial cGMP accumulation. Kidney Int. 40, 188-194
36. Wallace, A. W. and Tom, W. L. (2000) Interaction of L-arginine and phosphodiesterase inhibitors in vasodilation of the porcine internal mammary artery. Anesth. Analg. 90, 840-846
37. Delpy, E. and le Monnier de Gouville, A. C. (1996) Cardiovascular effects of a novel, potent and selective phosphodiesterase 5 inhibitor, DMPPO: in vitro and in vivo characterization. Br. J. Pharmacol. 118, 1377-1384
38. Zusman, R. M., Prisant, L. M. and Brown, M. J. (2000) Effect of sildenafil citrate on blood pressure and heart rate in men with erectile dysfunction taking concomitant antihypertensive medication. Sildenafil Study Group. J. Hypertens. 18, 1865-1869
39. Kloner, R. A., Brown, M., Prisant, L. M. and Collins, M. (2001) Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Sildenafil Study Group. Am. J. Hypertens. 14, 70-73
40. Koh, K. K., Bui, M. N., Hathaway, L. et al. (1999) Mechanism by which quinapril improves vascular function in coronary artery disease. Am. J. Cardiol. 83, 327-331
41. Mombouli, J. V., Illiano, S., Nagao, T., Scott-Burden, T. and Vanhoutte, P. M. (1992) Potentiation of endothelium-dependent relaxations to bradykinin by angiotensin I converting enzyme inhibitors in canine coronary artery involves both endothelium-derived relaxing and hyperpolarizing factors. Circ. Res. 71, 137-144
42. Nakamura, M., Funakoshi, T., Arakawa, N., Yoshida, H., Makita, S. and Hiramori, K. (1994) Effect of angiotensin-converting enzyme inhibitors on endothelium-dependent peripheral vasodilation in patients with chronic heart failure. J. Am. Coll. Cardiol. 24, 1321-1327
43. Phillips, B. G., Kato, M., Pesek, C. A. et al. (2000) Sympathetic activation by sildenafil. Circulation 102, 3068-3073
44. Katz, S. D. (1995) The role of endothelium-derived vasoactive substances in the pathophysiology of exercise intolerance in patients with congestive heart failure. Prog. Cardiovasc. Dis. 28, 23-50
45. Nakamura, M., Ishikawa, M., Funakoshi, T., Hashimoto, K., Chiba, M. and Hiramori, K. (1994) Attenuated endothelium-dependent peripheral vasodilation and clinical characteristics in patients with chronic heart failure. Am. Heart J. 128, 1164-1169
46. Katz, S. D., Khan, T., Zeballos, G. A. et al. (1999) Decreased activity of the L-arginine-nitric oxide metabolic pathway in patients with congestive heart failure. Circulation 99, 2118-2123